September 16, 2022
A Brooklyn federal judge has given an initial nod to the proposed $11.5 million settlement of investors' claims that Vanda Pharmaceuticals Inc. hid from the public that it was illegally marketing its drugs for off-label use.
March 10, 2021
A New York federal judge declined Wednesday to allow Vanda Pharmaceuticals Inc. or its CEO to slip a proposed securities class action alleging the company misled investors by aggressively marketing drugs for nonapproved uses, but he did allow three other Vanda executives out of the case.
February 25, 2019
Disgruntled Vanda Pharmaceuticals Inc. shareholders filed a proposed securities class action against the company Monday that alleges Vanda executives misled investors for years by aggressively marketing drugs for nonapproved uses to juice profits.